Skip Navigation
National Cancer Institute
National Cancer Institute U.S. National Institutes of Health National Cancer Institute
 
OverviewProgramsAccomplishmentsEvent ListingNews and HighlightsPublished Research
 

Nanomaterials for Cancer Diagnostics and Therapeutics
Northwestern University

Center Investigators

Chad A. Mirkin, Ph.D.
Principal Investigator

 

Steven T. Rosen, M.D.
Principal Investigator

Cores

Core A: Nanoconstructs

Core Investigator: Teri W. Odom, Ph.D.
The Nanoconstructs Core plays a critical role in standardizing agents for therapeutics, diagnostics, and imaging by serving as a resource for test-bedding and a clearinghouse for CCNE-developed nanoconstructs. A single source that can provide quality-controlled, highly uniform nanoparticle probes promotes and enables better integration across all CCNE projects—which ensures improved nano-cancer research connections as well as expediting the use of nanotechnology in clinical treatments of cancer. The Core works closely with the individual projects in a feed-back and feed-forward manner and also serves to nucleate the development of a local community with expertise in nanoscale synthesis and fabrication and characterization of nanomaterials coupled to biologically relevant molecules.

Core B: Bioinformatics

Core Investigator: Warren Kibbe, Ph.D.
The Bioinformatics Core supports NU-CCNE investigators with bioinformatics services and computational support for molecular imaging, genomics, and proteomics. The Core provides educational opportunities, data sharing, and the capacity to link with the NCI Center for Bioinformatics. State of the art algorithms for pathway analysis, microarray analysis, proteomics, good software development practices, and data handling and computational resources are available to NU-CCNE members. These activities include applying the Cancer Center's clinical trials and translational informatics infrastructure to new drug and device trials emerging from the CCNE; profiling and unraveling the molecular targets and effects of CCNE-developed compounds by high throughput - omic techniques; integrating clinical data from the Northwestern Medicine Enterprise Data Warehouse to the clinical research activities of the CCNE; and applying caNanoLab in support of the activities of the CCNE.